NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan

  • Written by ACN Newswire

image

TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase...

Read more: Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination...